These results suggested that glioma patients with low expression of ANXA2 and ANXA2 pseudogenes could benefit more from chemotherapy and radiotherapy, and highly expressed ANXA2, ANXA2P1 and ANXA2P2 could be an indication of poor response to adjuvant therapy. Here, ANXA2P2 is linked to central nervous system cancer.